---

---

tags : Phase 2    symbols : Alny   

save search

---

Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
Published: 2022-09-22 (Crawled : 13:20) - biospace.com/
VIR | $7.96 0.0% 1.1M |

Health Technology

| -55.88% | O: -1.55% H: 2.68% C: 1.2%
ALNY | News | $144.315 -0.58% -0.59% 700K |

Health Technology

| -29.67% | O: -0.53% H: 0.0% C: -1.26%
vir-2218 treatment hepatitis vir-3434 virus trial infection phase 2

---

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-08-29 (Crawled : 13:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| 9.64% | O: -1.08% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| 51.16% | O: -0.64% H: 1.24% C: 0.07%
ALNY | News | $144.315 -0.58% -0.59% 700K |

Health Technology

| -31.18% | O: -0.56% H: 1.41% C: -0.34%
treatment nephropathy positive study phase 2

---

Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-06-09 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -14.39% | O: -0.88% H: 0.0% C: 0.0%
ALNY | News | $144.315 -0.58% -0.59% 700K |

Health Technology

| 6.56% | O: 1.59% H: 0.68% C: -2.46%
treatment nephropathy topline positive phase 2

---

New Results from Phase 1 Study of Cemdisiran + Pozelimab Presented at ASH Annual Meeting 2021
Published: 2021-12-14 (Crawled : 03:00) - alnylam.com
ALNY | News | $144.315 -0.58% -0.59% 700K |

Health Technology

| -17.38% | O: 6.02% H: 2.03% C: -0.29%
phase 1 results phase 2 phase 3

---

Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
Published: 2021-11-08 (Crawled : 13:00) - biospace.com/
ALNY | News | $144.315 -0.58% -0.59% 700K |

Health Technology

| -21.75% | O: 1.43% H: 0.0% C: 0.0%
phase 2 hypertension

---

Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | $122.71 -0.03% 0.17% 5M |

Health Technology

| 42.3% | O: 0.9% H: 0.72% C: 0.58%
LLY | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 219.45% | O: 0.58% H: 0.42% C: 0.38%
ALNY | News | $144.315 -0.58% -0.59% 700K |

Health Technology

| -20.75% | O: 0.45% H: 0.0% C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3

---

Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection
Published: 2021-07-15 (Crawled : 14:00) - biospace.com/
VIR | $7.96 0.0% 1.1M |

Health Technology

| -76.71% | O: 0.08% H: 2.71% C: 2.31%
ALNY | News | $144.315 -0.58% -0.59% 700K |

Health Technology

| -14.78% | O: -0.16% H: 1.35% C: 1.11%
phase 2 hepatitis biotech technology iot trial injection infections chronic hepatitis b

---

Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
Published: 2021-06-30 (Crawled : 12:00) - biospace.com/
ALNY | News | $144.315 -0.58% -0.59% 700K |

Health Technology

| -12.49% | O: -0.28% H: 5.14% C: 2.48%
phase 2 hypertension

---

Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | $122.71 -0.03% 0.17% 5M |

Health Technology

| 50.67% | O: -0.39% H: 0.27% C: -0.21%
LLY | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 237.17% | O: -0.02% H: 0.44% C: -0.53%
ALNY | News | $144.315 -0.58% -0.59% 700K |

Health Technology

| -15.24% | O: 0.08% H: 1.01% C: 0.9%
disease liver disease treatment phase 2 liver trial

---

Complete Results from Phase 1/2 Study of Lumasiran (OXLUMO®) Published in Clinical Journal of the American Society of Nephrology
Published: 2021-05-15 (Crawled : 04:20) - alnylam.com
ALNY | News | $144.315 -0.58% -0.59% 700K |

Health Technology

| Email alert Add to watchlist
phase 1 results phase 3 phase 2

---

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Published: 2021-04-21 (Crawled : 12:00) - vbivaccines.com
VIR | $7.96 0.0% 1.1M |

Health Technology

| -82.98% | O: -1.09% H: 0.38% C: 0.04%
VBIV | $0.6396 1.57% 1.55% 160K |

Health Technology

| -75.86% | O: 0.0% H: 7.66% C: 7.66%
ALNY | News | $144.315 -0.58% -0.59% 700K |

Health Technology

| 6.71% | O: 0.67% H: 1.12% C: 0.43%
treatment phase 2 hepatitis vbi-2601 biotech vaccine technology iot brii-835 trial

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | News | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---